HRP20160285T1 - Predlijek adrenomedulina na bazi polietilen glikola i njegova uporaba - Google Patents

Predlijek adrenomedulina na bazi polietilen glikola i njegova uporaba Download PDF

Info

Publication number
HRP20160285T1
HRP20160285T1 HRP20160285TT HRP20160285T HRP20160285T1 HR P20160285 T1 HRP20160285 T1 HR P20160285T1 HR P20160285T T HRP20160285T T HR P20160285TT HR P20160285 T HRP20160285 T HR P20160285T HR P20160285 T1 HRP20160285 T1 HR P20160285T1
Authority
HR
Croatia
Prior art keywords
acute
compound according
compound
disease
prevention
Prior art date
Application number
HRP20160285TT
Other languages
English (en)
Inventor
Ingo Flamme
Johannes KÖBBERLING
Hans-Georg Lerchen
Nils Griebenow
Rudolf Schohe-Loop
Sven WITTROCK
Maria KÖLLNBERGER
Frank Wunder
Gorden Redlich
Andreas Knorr
July MARLEY
Iain PRITCHARD
Original Assignee
Bayer Pharma Aktiengesellschaft
Bayer Intellectual Property Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property Gmbh filed Critical Bayer Pharma Aktiengesellschaft
Publication of HRP20160285T1 publication Critical patent/HRP20160285T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)

Claims (12)

1. Spoj s formulom [image] naznačen time da n predstavlja broj 0, 1, 2 ili 3, R1 predstavlja vodik, metil, etil, n-propil ili izopropil, R2 predstavlja ravni ili razgranati PEG 20 kDa do 80 kDa koji kao završnu skupinu ima metoksi-skupinu, ili jedna od njegovih soli, njegovih solvata ili solvata njegovih soli.
2. Spoj prema zahtjevu 1, naznačen time da n predstavlja broj 1 ili 2, R1 predstavlja vodik ili metil, R2 predstavlja ravni PEG 40 kDa koji kao završnu skupinu ima metoksi-skupinu.
3. Spoj prema bilo kojem od zahtjeva 1 i 2, naznačen time da n predstavlja broj 1 ili 2, R1 predstavlja vodik, R2 predstavlja ravni PEG 40 kDa koji kao završnu skupinu ima metoksi-skupinu.
4. Postupak za pripravu spoja s formulom (I) ili jedna od njegovih soli, njegovih solvata ili solvata njegovih soli prema zahtjevu 1, naznačen time da spoj s formulom (II) [image] naznačen time da n i R1 su svaki kako je definirano u zahtjevu 1, reagira sa spojem s formulom (III) [image] u kojoj R2 je kako je definirano u zahtjevu 1.
5. Spoj prema bilo kojem od zahtjeva 1 do 3 naznačen time da je za liječenje i/ili sprječavanje bolesti.
6. Uporaba spoja prema bilo kojem od zahtjeva 1 do 3 naznačen time da je za proizvodnju lijeka za liječenje i/ili sprječavanje bolesti.
7. Uporaba spoja prema bilo kojem od zahtjeva 1 do 3 naznačen time da je za proizvodnju lijeka za liječenje i/ili sprječavanje kardiovaskularnih, edematoznih i/ili upalnih poremećaja.
8. Lijek koji sadrži spoj prema bilo kojem od zahtjeva 1 do 3 naznačen time da je u kombinaciji s inertnim netoksičnim farmaceutski prihvatljivim pomoćnim sredstvom.
9. Lijek koji sadrži spoj prema bilo kojem od zahtjeva 1 do 3 naznačen time da je u kombinaciji s dodatnom aktivnom tvari.
10. Lijek prema zahtjevu 8 ili 9 naznačen time da je za liječenje i/ili sprječavanje kardiovaskularnih, edematoznih i/ili upalnih poremećaja.
11. Uporaba spoja prema bilo kojem od zahtjeva 1 do 3 naznačen time da je za proizvodnju lijeka za liječenje i/ili sprječavanje zatajenja srca, koronarne srčane bolesti, ishemijskog i/ili hemoragijskog moždanog udara, hipertenzije, plućne hipertenzije, bolesti začepljenja perifernih arterija, preeklampsije, kronične opstruktivne plućne bolesti, astme, akutnog i/ili kroničnog plućnog edema, alergijskog alveolitisa i/ili pneumonitisa zbog udahnute organske prašine i čestica gljivica, čestica aktinomiceta ili čestica drugog podrijetla, i/ili akutnog kemijskog bronhitisa, akutnog i/ili kroničnog kemijskog plućnog edema, neurogenog plućnog edema, akutnih i/ili kroničnih plućnih manifestacija zbog zračenja, akutne i/ili kronične intersticijske plućne bolesti, akutnog oštećenja pluća/akutnog respiratornog distres sindroma (ALI/ARDS) kod odraslih ili djece uključujući novorođenčad, sekundarnog ALI/ARDS uz upalu pluća i sepsu, aspiracijske upale pluća i sekundarnog ALI/ARDS zbog aspiracije, sekundarnog ALI/ARDS zbog udisanja dimnih plinova, akutnog oštećenja pluća uzrokovanog transfuzijom (TRALI), ALI/ARDS i/ili akutne plućne insuficijencije nakon operativnih zahvata, trauma i/ili opekotina, i/ili ozljede pluća izazvane ventilatorom (VILI), ozljede pluća poslije aspiracije mekonija, plućne fibroze, visinske bolesti, kroničnih bolesti bubrega, glomerulonefritisa, akutnog oštećenja bubrega, kardiorenalnog sindroma, limfedema, upalne bolesti crijeva, sepse, septičkog šoka, sindroma sistemskog upalnog odgovora (SIRS) ne-infektivnog porijekla, anafilaktičkog šoka, upalne bolesti crijeva i/ili urtikarije.
12. Spoj kako je definiran u bilo kojem od zahtjeva 1 do 3 naznačen time da je za uporabu u postupku liječenja i/ili sprječavanja kardiovaskularnih, edematoznih i/ili upalnih poremećaja.
HRP20160285TT 2011-11-03 2016-03-21 Predlijek adrenomedulina na bazi polietilen glikola i njegova uporaba HRP20160285T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11187735 2011-11-03
PCT/EP2012/071507 WO2013064508A1 (en) 2011-11-03 2012-10-30 Polyethylene glycol based prodrug of adrenomedullin and use thereof
EP12783566.8A EP2773376B1 (en) 2011-11-03 2012-10-30 Polyethylene glycol based prodrug of adrenomedullin and use thereof

Publications (1)

Publication Number Publication Date
HRP20160285T1 true HRP20160285T1 (hr) 2016-04-22

Family

ID=47146369

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20160285TT HRP20160285T1 (hr) 2011-11-03 2016-03-21 Predlijek adrenomedulina na bazi polietilen glikola i njegova uporaba
HRP20180319TT HRP20180319T1 (hr) 2011-11-03 2018-02-21 Predlijek adrenomedulina baziran na polietilen glikolu i njegova uporaba

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20180319TT HRP20180319T1 (hr) 2011-11-03 2018-02-21 Predlijek adrenomedulina baziran na polietilen glikolu i njegova uporaba

Country Status (45)

Country Link
US (3) US9603936B2 (hr)
EP (2) EP2773376B1 (hr)
JP (2) JP5995984B2 (hr)
KR (2) KR102004668B1 (hr)
CN (2) CN107412740B (hr)
AR (2) AR088582A1 (hr)
AU (2) AU2012331244B2 (hr)
BR (1) BR112014010708B1 (hr)
CA (1) CA2854134C (hr)
CL (1) CL2014000948A1 (hr)
CO (1) CO7020863A2 (hr)
CR (1) CR20140184A (hr)
CU (1) CU24184B1 (hr)
CY (2) CY1117354T1 (hr)
DK (2) DK3075395T3 (hr)
DO (2) DOP2014000078A (hr)
EA (2) EA029410B1 (hr)
EC (2) ECSP14013326A (hr)
ES (2) ES2659195T3 (hr)
GT (1) GT201400085A (hr)
HK (1) HK1246147A1 (hr)
HR (2) HRP20160285T1 (hr)
HU (2) HUE036535T2 (hr)
IL (3) IL232037B (hr)
IN (1) IN2014CN03290A (hr)
JO (2) JOP20190001B1 (hr)
LT (1) LT3075395T (hr)
MA (1) MA35618B1 (hr)
ME (1) ME02379B (hr)
MX (2) MX361287B (hr)
MY (2) MY173372A (hr)
NO (1) NO3075395T3 (hr)
PE (2) PE20141219A1 (hr)
PL (2) PL2773376T3 (hr)
PT (1) PT3075395T (hr)
RS (2) RS54623B1 (hr)
SG (2) SG11201400924TA (hr)
SI (2) SI2773376T1 (hr)
TN (1) TN2014000185A1 (hr)
TR (1) TR201802124T4 (hr)
TW (2) TWI583396B (hr)
UA (1) UA111098C2 (hr)
UY (2) UY34419A (hr)
WO (1) WO2013064508A1 (hr)
ZA (1) ZA201600434B (hr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6051223B2 (ja) * 2011-11-03 2016-12-27 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ ペプチドの放出可能な結合のためのチロシンに基づくリンカー
EP2896400A1 (en) * 2014-01-17 2015-07-22 Université Catholique De Louvain Method for increasing the bioavailability of inhaled compounds
JP6685046B2 (ja) * 2014-03-20 2020-04-22 国立大学法人 宮崎大学 長時間作用型アドレノメデュリン誘導体
AU2015323769A1 (en) 2014-09-26 2017-04-13 Bayer Pharma Aktiengesellschaft Stabilized adrenomedullin derivatives and use thereof
CA2997131C (en) * 2015-09-18 2021-05-25 University Of Miyazaki Long-acting adrenomedullin derivative
WO2018181638A1 (ja) 2017-03-29 2018-10-04 国立大学法人宮崎大学 長時間作用型アドレノメデュリン誘導体
GB201707938D0 (en) * 2017-05-17 2017-06-28 Univ Sheffield Compounds
CN114174326A (zh) 2019-06-18 2022-03-11 拜耳公司 长期稳定的肾上腺髓质素类似物及其用途
JP7498882B2 (ja) * 2019-12-05 2024-06-13 国立大学法人 宮崎大学 異常タンパク質蓄積性神経変性疾患の治療剤
AU2021249447A1 (en) * 2020-04-03 2022-11-03 Bayer Aktiengesellschaft Liquid pharmaceutical formulations polyethylene glycol-based prodrugs of adrenomedullin and use
CN115666654A (zh) 2020-04-03 2023-01-31 拜耳公司 药物制剂聚乙二醇基肾上腺髓质素前药和用途
EP4211171A2 (en) 2020-09-10 2023-07-19 Precirix N.V. Antibody fragment against fap
CN112457218B (zh) * 2020-11-05 2022-08-09 宁夏医科大学 2,4-二氨基丁酸衍生物的合成方法
AU2022330343A1 (en) 2021-08-20 2024-02-08 Bayer Aktiengesellschaft Process for the preparation of pegylated adrenomedullin, its intermediates and use thereof
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5020040A (en) * 1987-06-24 1991-05-28 Digital Equipment Corporation Overwriting system for magneto-optical recording with self timing track
US4812590A (en) 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
CA2292902C (en) 1999-12-24 2012-12-18 Alain Cadieux Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2004019993A1 (en) 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
US7705045B2 (en) 2002-11-14 2010-04-27 Syntarga, B.V. Prodrugs built as multiple self-elimination-release spacers
EP1646813B1 (en) 2003-07-23 2013-06-12 PPG Industries Ohio, Inc. Composite seal and window assembly
AU2005232371B2 (en) 2004-03-23 2010-10-14 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
EP1749026B1 (en) 2004-05-24 2011-11-23 Institut de Cardiologie de Montréal Labelled adrenomedullin derivatives and their use for imaging and therapy
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8273325B2 (en) * 2006-12-20 2012-09-25 Ge Healthcare As Contrast agents
WO2008138141A1 (en) 2007-05-11 2008-11-20 Institut De Cardiologie De Montréal Labelled adrenomedullin derivatives and their use for imaging and therapy.
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
JP6051223B2 (ja) * 2011-11-03 2016-12-27 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ ペプチドの放出可能な結合のためのチロシンに基づくリンカー

Also Published As

Publication number Publication date
AU2012331244B2 (en) 2017-06-15
TWI583396B (zh) 2017-05-21
IL232037A0 (en) 2014-05-28
LT3075395T (lt) 2018-02-26
KR20180108892A (ko) 2018-10-04
MX2014004384A (es) 2014-04-30
GT201400085A (es) 2015-03-05
KR101965467B1 (ko) 2019-04-03
CN103998063B (zh) 2016-09-21
KR20150000462A (ko) 2015-01-02
ME02379B (me) 2016-06-20
US9603936B2 (en) 2017-03-28
CL2014000948A1 (es) 2014-09-05
PE20141219A1 (es) 2014-09-13
JP2017014264A (ja) 2017-01-19
DOP2014000078A (es) 2014-07-15
CO7020863A2 (es) 2014-08-11
UY34419A (es) 2013-05-31
CU24184B1 (es) 2016-07-29
CR20140184A (es) 2014-05-27
MX350341B (es) 2017-09-04
EP2773376A1 (en) 2014-09-10
PL2773376T3 (pl) 2016-07-29
JP6177975B2 (ja) 2017-08-09
PT3075395T (pt) 2018-02-13
IL252281B (en) 2021-01-31
MA35618B1 (fr) 2014-11-01
ECSP18071104A (es) 2018-10-31
HRP20180319T1 (hr) 2018-03-23
JOP20190001A1 (ar) 2017-06-16
WO2013064508A1 (en) 2013-05-10
CU20140051A7 (es) 2014-10-02
RS56819B1 (sr) 2018-04-30
AU2017203423A1 (en) 2017-06-08
US20170204137A1 (en) 2017-07-20
ECSP14013326A (es) 2014-05-31
NZ622997A (en) 2015-12-24
UY37922A (es) 2018-11-30
IL252281A0 (en) 2017-08-31
ES2568063T3 (es) 2016-04-27
EP3075395A1 (en) 2016-10-05
TR201802124T4 (tr) 2018-03-21
CN107412740B (zh) 2021-02-09
HUE036535T2 (hu) 2018-07-30
JO3385B1 (ar) 2019-03-13
BR112014010708B1 (pt) 2021-03-02
CY1117354T1 (el) 2017-04-26
AU2012331244A1 (en) 2014-04-17
US20140287984A1 (en) 2014-09-25
BR112014010708A2 (pt) 2017-04-25
CN103998063A (zh) 2014-08-20
NZ714621A (en) 2017-10-27
CA2854134C (en) 2020-04-21
DK2773376T3 (en) 2016-04-18
PL3075395T3 (pl) 2018-04-30
AU2017203423B2 (en) 2019-01-31
TW201332573A (zh) 2013-08-16
US10035818B2 (en) 2018-07-31
EP2773376B1 (en) 2016-01-13
TW201720467A (zh) 2017-06-16
HUE027333T2 (en) 2016-09-28
IL258229A (en) 2018-06-28
US9649363B2 (en) 2017-05-16
HK1246147A1 (zh) 2018-09-07
JP2014532682A (ja) 2014-12-08
JP5995984B2 (ja) 2016-09-21
IN2014CN03290A (hr) 2015-07-03
DOP2018000203A (es) 2018-10-15
RS54623B1 (en) 2016-08-31
KR102004668B1 (ko) 2019-07-26
US20160367636A1 (en) 2016-12-22
MY194197A (en) 2022-11-21
SI3075395T1 (en) 2018-03-30
DK3075395T3 (en) 2018-02-19
SG10201607516SA (en) 2016-10-28
CA2854134A1 (en) 2013-05-10
ZA201600434B (en) 2017-05-31
MY173372A (en) 2020-01-21
CN107412740A (zh) 2017-12-01
CY1119897T1 (el) 2018-06-27
EA201600495A1 (ru) 2016-10-31
PE20181493A1 (es) 2018-09-18
NO3075395T3 (hr) 2018-04-21
SG11201400924TA (en) 2014-09-26
JOP20190001B1 (ar) 2022-03-14
ES2659195T3 (es) 2018-03-14
EA029410B1 (ru) 2018-03-30
MX361287B (es) 2018-12-03
TN2014000185A1 (en) 2015-09-30
EA025631B1 (ru) 2017-01-30
IL232037B (en) 2018-12-31
SI2773376T1 (sl) 2016-05-31
UA111098C2 (uk) 2016-03-25
AR113830A2 (es) 2020-06-17
AR088582A1 (es) 2014-06-18
IL258229B (en) 2020-02-27
EA201400528A1 (ru) 2014-10-30
TWI653051B (zh) 2019-03-11
EP3075395B1 (en) 2017-11-22

Similar Documents

Publication Publication Date Title
HRP20160285T1 (hr) Predlijek adrenomedulina na bazi polietilen glikola i njegova uporaba
PH12019501098A1 (en) Pyrrolopyrimidines as cftr potentiators
ES2368967T3 (es) Combinaciones de benzotiazol agonista del adrenorreceptor beta 2.
HRP20200429T1 (hr) 3,5-diamino-6-kloro-n-(n-(4-(4-(2-(heksil(2,3,4,5,6-penta-hidroksiheksil)amino)etoksi)fenil)butil)karbamimidoil)pirazin-2-karboksamid
HRP20171044T1 (hr) Kemijski i metabolički stabilni dipeptid s potentnom aktivnošću blokatora natrijevog kanala
JP2012503668A5 (hr)
HRP20100359T1 (hr) Specifični glukokortikoidni spoj s protuupalnom aktivnošću
JP2018505192A5 (hr)
EA201270561A1 (ru) Антагонисты рецептора cgrp
JP2012025755A5 (hr)
HRP20120708T1 (hr) Kombinacija antikolinergika, glukokortikoida i beta2-agonista za lijeäśenje upalnih bolesti
JP2015517489A5 (hr)
RU2015144083A (ru) Комбинация лекарственных средств
CO6640319A2 (es) Formulación en polvo seca que comprende una droga antimuscarínica
CL2009000198A1 (es) Compuestos derivados del acido {2'-[(amino n,n-disustituido)-metil]-bifenil-3-il} acetico, mediadores de prostaglandina d2; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad respiratoria, alergica o inflamatoria, tal como el asma, epoc o rinitis alergica.
WO2011141929A3 (en) Aqueous pharmaceutical compositions of fluticasone and olopatadine
RU2019121673A (ru) Активаторы nrf2
EA201590019A1 (ru) Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы
JP2020516689A5 (hr)
JP2012509922A5 (hr)
JP2009532413A5 (hr)
JP2014520854A5 (hr)
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
JP2018520986A5 (hr)
SG188575A1 (en) Novel combinations